ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Antilymphocyte antibodies"

  • 2018 American Transplant Congress

    Survey of Rabbit Anti-Thymocyte Globulin Usage for Kidney Transplant Induction Therapy in the United States

    K. Foster,1 A. Dodson,2 K. Gutierrez.2

    1Samford University McWhorter School of Pharmacy, Birmingham, AL; 2Comprehensive Transplant Institute, UAB Hospital, Birmingham, AL.

    Background: Rabbit anti-thymocyte globulin (rATG) has become the most widely used induction agent in kidney transplantation (KTx) and has recently received FDA approval for this…
  • 2018 American Transplant Congress

    Outcomes Associated with Rabbit Anti-Thymocyte Globulin Induction According to Mg/Kg of Total Body Weight in Kidney Transplant Recipients

    A. Brueckner, A. Logan, L. Bowman.

    Pharmacy, Tampa General Hospital, Tampa, FL.

    Purpose: The optimal dosing weight used for rabbit anti-thymocyte globulin (rATG) induction therapy in transplantation continues to lack a consensus. The impact of alternative dosing…
  • 2017 American Transplant Congress

    B Cell-Derived Cytokines Rather Than T/B Cognate Interactions Mediate CD8 T Cell Reconstitution Following Lymphoablation.

    D. Zwick, K. Ayasoufi, R. Fan, V. Gorbacheva, K. Keslar, R. Fairchild, A. Valujskikh.

    Immunology, Cleveland Clinic, Cleveland, OH

    Antibody-mediated lymphoablation is a commonly used induction therapy in sensitized transplant recipients. Using murine anti-thymocyte globulin (mATG) in a model of BALB/c (H-2d) to B6…
  • 2017 American Transplant Congress

    Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.

    E. Ko,1,2 J. Yu,1,2 B. Choi,1,2 C. Park,1,2 Y. Kim,1,2 C. Yang,1,2 B. Chung.1,2

    1Transplant Research Center, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; 2Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea

    Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…
  • 2017 American Transplant Congress

    Using Basiliximab Does Not Increase De Novo DSA Incidence but Reduces Cytomegalovirus Infections and Neoplastic Complications in Non-Sensitized Kidney Transplant Patients.

    M. Marron-Wojewodzki,1 I. Szwarc,1 C. Rene,2 J.-F. Eliaou,2 G. Mourad,1 M. Le Quintrec.1,3

    1Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, Montpellier University Hospital, Montpellier, France; 2Departement of Immunology, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France; 3Inserm U1183, IRMB, Hôpital Saint Eloi, Montpellier University Hospital, Montpellier, France

    Background. In kidney transplantation, de novo donor specific antibodies (dnDSA) are associated with antibody-mediated rejection (AMR) and graft failure. After dnDSA development, 24% of the…
  • 2017 American Transplant Congress

    Biomarkers of Epithelial-Mesenchymal Transition (EMT) in Chronic Allograft Nephropathy: Potential for Early Detection and Development of Novel Therapeutic Agents.

    S. Kanangat, R. Miller, S. Rezaeian, H. Eldib, D. Cimbaluk, C. Fhied, I. Kurbegovic-Skaljic, M. Prod, J. Borgia, M. Flaws, D. Castillo, R. DeCresce.

    Pathology, BioChemistry and Medical Laboratory Sciences, Rush University Medical Center, Chicago, IL

    Purpose: To detect markers and novel treatment targets related to fibrogenesis and eventual graft loss by focusing on Epithelial Mesenchymal transition (EMT) which requires understanding…
  • 2016 American Transplant Congress

    Anti-Thymocyte Globulin Induction Does Not Increase the Risk of Thrombotic Events in Kidney Transplantation: A Matched Case-Control Study.

    J. Iuppa,1 M. Dokus,2 E. Venniro,3 A. Patel,2 A. Danzig,4 J. Hahn,1 R. Kashyap,2 M. Orloff,2 J. Taylor.3

    1Department of Pharmacy, University of Rochester, Rochester, NY; 2Department of Surgery, Division of Transplantation and Hepatobiliary Surgery, University of Rochester, Rochester, NY; 3Department of Medicine, Division of Nephrology, University of Rochester, Rochester, NY; 4School of Medicine and Dentistry, University of Rochester, Rochester, NY.

    Background: Anti-thymocyte globulin (ATG) is the most commonly used induction agent in kidney transplantation (KTx). To date, case reports and in vitro analyses have suggested…
  • 2016 American Transplant Congress

    Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.

    G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli.

    Surgery - Renal Transplant Unit, Università Cattolica del Sacro Cuore, Rome, Italy.

    Introduction.Aim of this study was to evaluate the efficacy and safety of preemptive prophylaxis of CMV infection in kidney transplant recipients (KTx) receiving polyclonal antibodies…
  • 2016 American Transplant Congress

    Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.

    M. McRae, T. How, A. Kirk, H. Xu.

    Department of Surgery, Duke University, Durham, NC.

    Belatacept-based maintenance regimens prevent acute allograft rejection following alemtuzumab induction, and patients so treated maintain intact anti-CMV and -EBV T cell immune responses without viral…
  • 2016 American Transplant Congress

    Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.

    E. Schrezenmeier,1 T. Doerner,2 O. Staeck,1 K. Budde,1 F. Halleck.1

    1Nephrology, Charité, Berin, Germany; 2Rheumatology, Charité, Berlin, Germany.

    BACKGROUND:Rituximab off-label use is common in solid organ transplantation. It is used in patients with antibody-mediated rejections, in AB0-incompatible renal transplantation, in pre-sensitized organ recipients…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences